about
Cost-effectiveness analysis of preoperative transfusion in patients with sickle cell disease using evidence from the TAPS trial.When does NICE recommend the use of health technologies within a programme of evidence development? : a systematic review of NICE guidanceCost-effectiveness of biologic agents for treatment of autoimmune disorders: structured review of the literature.Measuring Alzheimer disease progression with transition probabilities: estimates from NACC-UDS.Health economics of asthma: assessing the value of asthma interventions.Dependence as a unifying construct in defining Alzheimer's disease severityBidirectional citation searching to completion: an exploration of literature searching methods.The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a CritiMethods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold.Cost-Effectiveness Uncertainty Analysis Methods: A Comparison of One-Way Sensitivity, Analysis of Covariance, and Expected Value of Partial Perfect Information.A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B.Cost Effectiveness of Treatments for Chronic Constipation: A Systematic Review.The clinical and cost-effectiveness of the BRinging Information and Guided Help Together (BRIGHT) intervention for the self-management support of people with stage 3 chronic kidney disease in primary care: study protocol for a randomized controlled tDeveloping key performance indicators for prescription medication systemsRevisiting the cost-effectiveness of omalizumabThe costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspectiveThe Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trialAssessing the value of screening tools: reviewing the challenges and opportunities of cost-effectiveness analysis
P50
Q34516361-7E1537F8-9600-45DC-BA5E-E5C78B7E893CQ36579754-407D95D8-7C08-4FAA-8E26-15DD75F1A032Q36645816-B209B034-2CB8-4DE7-BAA8-DC516A073349Q36949519-078938AA-6110-46DE-BC7E-21E79FF174A1Q37334377-066E72D6-E805-4AD0-807B-EFED52B22E9DQ37448832-73F3829D-DBBB-4D3E-AD52-7539E9DA1269Q38242030-5346A794-BA82-48B7-B4AA-FE3DBBBF1185Q38330431-5EA75183-9441-40DC-B79E-136E6B7261E1Q39037720-A213CD4E-E60A-405B-960B-BCCD3A6111F0Q41687074-BB6BB602-B86F-482F-A6EA-C4A0D6889DECQ46319345-088C0BE8-5452-46F5-A7D5-10AEDAAF621CQ48203140-CCDEB510-5221-4DAA-B00A-FC82FFEF2EB9Q57520867-FA64F2C3-5C3F-453D-8E19-6E76878DE57DQ61817415-16224238-9120-43BE-9340-D9269F1A8622Q81553552-B04C753C-B8BE-4349-AB78-582282277709Q82865636-A6C74685-EDED-44DF-94A1-D9E62B15CBB7Q85960268-A45E6224-02FB-4613-B52C-DFC1E9601870Q90223477-2AFA533F-B94B-45F4-AE5B-519551596FB0
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Eldon Spackman
@en
Eldon Spackman
@nl
type
label
Eldon Spackman
@en
Eldon Spackman
@nl
prefLabel
Eldon Spackman
@en
Eldon Spackman
@nl
P31
P496
0000-0001-8558-5973